DrugPatentWatch Database Preview
Par Pharm Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for PAR PHARM, and what generic alternatives to PAR PHARM drugs are available?
PAR PHARM has two hundred and twenty-two approved drugs.
There is one US patent protecting PAR PHARM drugs. There are seventeen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and eighty supplementary protection certificates in thirteen countries.
Summary for Par Pharm
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 140 |
| Ingredients: | 137 |
| NDAs: | 222 |
| Patent Litigation for Par Pharm: | See patent lawsuits for Par Pharm |
| PTAB Cases with Par Pharm as petitioner: | See PTAB cases with Par Pharm as petitioner |
Drugs and US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm | HYDROXYUREA | hydroxyurea | CAPSULE;ORAL | 075340-001 | Feb 24, 1999 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Par Pharm Inc | AMLODIPINE BESYLATE AND VALSARTAN | amlodipine besylate; valsartan | TABLET;ORAL | 090011-001 | Mar 28, 2013 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Par Pharm Inc | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 211991-001 | Oct 23, 2019 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Par Pharm | IMIPRAMINE HYDROCHLORIDE | imipramine hydrochloride | TABLET;ORAL | 089497-001 | Jul 14, 1987 | DISCN | No | No | Start Trial | Start Trial | |||||
| Par Pharm | OMEPRAZOLE AND SODIUM BICARBONATE | omeprazole; sodium bicarbonate | FOR SUSPENSION;ORAL | 079182-002 | Apr 19, 2013 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-001 | Approved Prior to Jan 1, 1982 | 5,238,924 | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-004 | Jun 13, 1995 | 5,238,924 | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-001 | Approved Prior to Jan 1, 1982 | 4,105,776 | Start Trial |
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-005 | Jan 17, 1985 | 5,238,924 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg and 20 mg | ➤ Subscribe | 2008-02-29 |
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for Par Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1948613 | Start Trial |
| South Korea | 20080000660 | Start Trial |
| Canada | 2605413 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2006115626 | Start Trial |
| Australia | 2006240490 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0237929 | 68/1997 | Austria | Start Trial | PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827 |
| 1769785 | C300521 | Netherlands | Start Trial | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 |
| 0663916 | SPC/GB10/003 | United Kingdom | Start Trial | PRODUCT NAME: EVEROLIMUS; REGISTERED: SE SE 18690-18695 20030718; UK EU/1/09/538/001 20090803; UK EU/1/09/538/002 20090803; UK EU/1/09/538/003 20090803; UK EU/1/09/538/004 20090803; UK EU/1/09/538/005 20090803; UK EU/1/09/538/006 20090803 |
| 1874117 | SPC/GB14/041 | United Kingdom | Start Trial | PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121 |
| 0480717 | 98C0022 | France | Start Trial | PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
